Structural modifications of both the Victoza and Ozempic molecules prevent degradation by DPP-4 and prolong incretin activity. Victoza is a GLP-1 analog with 97% similarity to human GLP-1. Ozempic is a GLP-1 analog with 94% similarity to human GLP-1.